A new clinical trial update for vosoritide was recorded on May 11, 2026. The study, registered as NCT06668805, is titled "A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment." It is a Phase 2 trial and its current status is listed as recruiting.
The trial is designed to enroll children with Noonan syndrome who have shown inadequate growth during or after treatment with human growth hormone. No results have been posted for this study at this time, and this update reflects only the trial's recruitment status and design as registered.
Vosoritide is an approved compound, and this trial represents an investigation of its use in a patient population and indication distinct from its approved use. Interested readers can review the full trial listing on ClinicalTrials.gov using the identifier NCT06668805 for further details on eligibility and enrollment.
For more background on this compound, see the linked compound overview.